Cellebrite
CLBT
27 hedge funds and large institutions have $201M invested in Cellebrite in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1,065% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $1.22M
11.61% more ownership
Funds ownership: 0% → 11.61% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSCM
Light Street Capital Management
Palo Alto,
California
|
+$71M |
| 2 |
IP
Isomer Partners
New York
|
+$41.8M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$28.7M |
| 4 |
CC
Crosslink Capital
Menlo Park,
California
|
+$23.1M |
| 5 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$23M |
Top Sellers
CLBT Hedge Fund Activity: Q3 2021 in Review
27 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Cellebrite (CLBT) for Q3 2021, worth a combined $201M.
Buyers outnumbered sellers: 27 funds opened new CLBT positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Light Street Capital Management, opening a new position worth an estimated $71M.
- 27 institutional investors held Cellebrite (CLBT) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $201M of Cellebrite stock for Q3 2021.
- 27 funds opened new Cellebrite positions in Q3 2021 and 0 closed out, a net change of +27 holders.
- The largest Cellebrite buyer in Q3 2021 was Light Street Capital Management, an estimated $71M added.
Based on aggregated 13F filings for Q3 2021.